Recordati S.p.A. | Cash Flow

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
Net Income before Extraordinaries
133,693.00
161,193.00
198,792.00
237,431.00
288,799.00
Depreciation, Depletion & Amortization
34,709.00
42,788.00
38,483.00
37,932.00
48,153.00
Other Funds
18,215.00
2,337.00
4,302.00
1,679.00
9,767.00
Funds from Operations
167,966.00
194,917.00
241,303.00
276,861.00
293,123.00
Changes in Working Capital
2,153.00
15,762.00
6,069.00
21,425.00
20,412.00
Net Operating Cash Flow
170,119.00
179,155.00
247,372.00
255,436.00
272,711.00
Capital Expenditures
78,100.00
25,107.00
33,690.00
36,941.00
320,700.00
Purchase/Sale of Investments
122,739.00
-
-
120,669.00
28.00
Net Investing Cash Flow
201,208.00
25,594.00
33,496.00
158,489.00
321,188.00
Cash Dividends Paid - Total
64,643.00
75,395.00
110,770.00
133,730.00
159,607.00
Issuance/Reduction of Debt, Net
143,274.00
2,877.00
12,894.00
5,524.00
351,168.00
Net Financing Cash Flow
66,905.00
68,842.00
125,341.00
189,819.00
212,061.00
Net Change in Cash
35,816.00
84,719.00
88,535.00
92,872.00
163,584.00
Free Cash Flow
157,794.00
156,924.00
216,133.00
235,767.00
258,123.00
Deferred Taxes & Investment Tax Credit
1,448.00
7,816.00
3,510.00
5,637.00
32,422.00
Other Sources
-
-
194.00
-
-
Change in Capital Stock
6,489.00
6,013.00
5,979.00
48,886.00
30,267.00
Other Uses
369.00
487.00
-
879.00
516.00

About Recordati

View Profile
Address
Via Matteo Civitali, 1
Milan Milan 20148
Italy
Employees -
Website http://www.recordati.it
Updated 09/14/2018
Recordati SpA engages in the research, development, manufacturing and marketing of pharmaceuticals. It operates through two segments: Pharmaceutical and Rare Diseases. The Pharmaceutical segment offers prescription and over-the-counter products as well as chemical syntheses, intermediates, and active ingredients for its proprietary and licensed brands.